Breaking Finance News

Rodman & Renshaw issued a report on (NYSE:VRX) Valeant Pharma, reducing its stock price target to $81 earlier today

Reporting a possible upside of 2.61%, Rodman & Renshaw lowered the target stock price of Valeant Pharma (NYSE:VRX) to $81

Previously on 6/23/2016, JP Morgan reported on Valeant Pharma(NYSE:VRX) suggesting “Overweight;Neutral” with a target price of $35 that indicated a possible upside of 0.60%.

Just yesterday Valeant Pharma (NYSE:VRX) traded 11.51% higher at $22.45. Valeant Pharma’s 50-day average is $22.18 and its 200-day average is $41.77. The last close is down 40.06% from the 200-day moving average, compared with the Standard & Poor’s 500 Index which has raised 0.00% over the date range. Volume of trade was was down over the average, with 21,886,253 shares of VRX changing hands under the typical 27,488,100 shares..

Performance Chart:

Valeant Pharma (NYSE:VRX)

Valeant Pharma has a one-year low of $18.55 and a one-year high of $253.62 . VRX’s total market value is currently $8.6B.

In addition to Rodman & Renshaw reporting it’s target price, a total of 18 brokers have issued a research note on the stock. The one year target price is $43.56 with three analysts rating the stock a strong buy, two firms rating the stock a buy, 10 analyts rating the stock a hold, four firms rating the company to underperform, and lastly one brokeragerating the stock as sell.

General Information About Valeant Pharma (NYSE:VRX)

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, and Crystalens and Trulign.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.